CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 40 target
Drug / intervention
Mesenchymal stem cells +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01765634
NCT01765634Phase 2Unknown
CompareCT.gov

Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease

Nanfang Hospital, Southern Medical University·interventional·Posted Jan 10, 2013·Updated Jan 10, 2013

In Brief

A Phase 2 clinical trial evaluating Mesenchymal stem cells and Non-mesenchymal stem cells for Acute Graft-versus-host Disease. Targeting 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the utility of treating patients experiencing refractory acute graft-versus-host disease with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. The objective was to evaluate the effect and safety of such treatment on refractory acute graft-versus-host disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Graft-versus-host Disease
CountriesChina
CollaboratorsSun Yat-sen University, Peking University People's Hospital, Guangdong Provincial People's Hospital, Guangzhou General Hospital of Guangzhou Military Command, Southern Medical University, China, Third Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou First People's Hospital, Zhongshan People's Hospital, Guangdong, China

Timeline

Phase 2UnknownOverdue
20132014201520162017201820192020202120222023202420252026
First PostedJan 10, 2013
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2016
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 13.5 years ago

Interventions

Mesenchymal stem cellsbiological

Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.

Non-mesenchymal stem cellsbiological

Other second line drugs are taken.